Deflazacort 地氟可特
CAS 14484-47-0 MFCD00866106
化学结构图
SMILES: CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C
化学属性
| Mol. Formula | C25H31NO6 |
|---|---|
| Mol. Weight | 441.52 |
| Melting Point | 252-258 |
别名和识别编码
| Chemical Name | Deflazacort |
|---|---|
| CAS Number | 14484-47-0 |
| Synonym | Deflazacort 11b,21-Dihydroxy-2'-methyl-5'bH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 21-acetate Calcort Dezacort azacort L-5458 L 5458 DL-458-IT Deflan (11?,16?)-21-(Acetyloxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 11β,21-dihydroxy-2'-methyl-5'βH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 2'-acetate (11β,16β)-21-(acetyloxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione Lantadin oxazacort (11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione (11β,16β)-21-(acetyloxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 11β,21-dihydroxy-2'-methyl-5'βH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 2'-acetate DL-458-IT L-5458 azacort oxazacort pregna-1,4-diene-11β,21-diol-3,20-dione[17α,16α-d]-2'-met |
| MDL Number | MFCD00866106 |
| EC Number | 238-483-7 |
| Chemical Name Translation | 地氟可特 |
| Wiswesser Line Notation | T F5 E5 B666 GN IO RV GU AHTTTT&J A1 CQ E1 FV1OV1 H1 |
| PubChem Substance ID | 253661789 |
| Reaxys-RN | 4947650 |
| Merck Number | 2862 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Bioactive Small Molecule Alphabetical Index, Corticosteroid, Cytokines, Growth Factors and Hormones, D-DIF, Hormones, Steroid Hormones, 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学
- Bioactive Small Molecules, Cell Biology, Cell Signaling and Neuroscience, Corticosteroid, Cytokines, Growth Factors and Hormones, D-DIF, Hormones, Steroid Hormones
产品应用
- A systemic corticosteroid. A derivative of prednisolone. Used for rheumatoid arthritis and lupus.
相关文献及参考
- Archer JD, Vargas CC, Anderson JE., Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J. 6 , 738-40, (2006)
- Cavall-Perin, P., et al.: Eur. J. Clin. Pharmacol., 26, 357 (1984),
- Nathansohn, G., et al.: J. Med. Chem., 10,799 (1967),
- Schiatti, P., et al.: Arzneim. Forsch., 30, 1543 (1980),
- Vandenburgh H, Shansky J, Benesch-Lee F, Skelly K, Spinazzola JM, Saponjian Y, Tseng BS., Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts. FASEB J. 10 , 3325-34, (2009)
- [1]. Mollmann, H., et al., Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharmaceutical research, 1995. 12(7): p. 1096-1100.
安全信息
GHS Symbol
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 5200 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1543,1980
